Analysts’ Weekly Ratings Updates for Achieve Life Sciences (ACHV)

Several brokerages have updated their recommendations and price targets on shares of Achieve Life Sciences (NASDAQ: ACHV) in the last few weeks:

• 8/13/2026 – Achieve Life Sciences is now covered by Morgan Stanley. They set an “overweight” rating and a $13.00 price target on the stock.
• 8/12/2026 – Achieve Life Sciences had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $18.00 price target on the stock.
• 8/12/2026 – Achieve Life Sciences had its “buy” rating reaffirmed by UBS Group AG.
• 8/12/2026 – Achieve Life Sciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $12.00 price target on the stock.
• 6/26/2026 – Achieve Life Sciences is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating and a $20.00 price target on the stock.
• 6/23/2026 – Achieve Life Sciences had its “buy” rating reaffirmed by UBS Group AG.
• 6/22/2026 – Achieve Life Sciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $12.00 price target on the stock.

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.